Barrington John Albert Furr
Plus aucun poste en cours
Profil
Barrington John Albert Furr served as a Non-Executive Chairman at Llangarth Ltd.
and as a Non-Executive Director at American Pharmaceutical Co. He was an Independent Director at GTx, Inc. from 2011 to 2015 and an Independent Non-Executive Director at Genus Plc from 2012 to 2014.
Furr also held various consulting positions at Abingworth Management Ltd., Medivir AB, Astex Therapeutics Ltd., Almirall Ltd., and Ipsen Bioinnovation Ltd.
He served as the Chief Scientist at AstraZeneca PLC and as the Chief Scientific Advisor at Evgen Ltd.
Furr was also a Non-Executive Director at Medicines & Healthcare Products Regulatory Agency.
He earned a doctorate degree from The University of Reading.
Anciens postes connus de Barrington John Albert Furr
| Sociétés | Poste | Fin |
|---|---|---|
| Medicines & Healthcare Products Regulatory Agency | Director/Board Member | 27/02/2015 |
Evgen Ltd.
 Evgen Ltd. Medical/Nursing ServicesHealth Services Evgen Ltd. develops novel glucosinolate based products for the prevention and treatment of human disease. It engages in the clinical stage drug development that lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. Its activities also include carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The firm holds proprietary technology that enables sulforaphane to be synthesized and then subsequently stabilized for pharmaceutical application. The company was founded by Dr. Stephen Franklin on October 18, 2007 and is headquartered in Liverpool, the United Kingdom. | Corporate Officer/Principal | 27/02/2015 |
GTx, Inc.
 GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | Director/Board Member | 27/02/2015 |
| Llangarth Ltd. | Chairman | 27/02/2015 |
American Pharmaceutical Co.
 American Pharmaceutical Co. Medical DistributorsDistribution Services American Pharmaceutical Co. is a leading advocate for the pharmacy profession and aims to create opportunities for pharmacists to play a key role in integrated patient care. The American company strives to ensure that the pharmacy profession is recognized as essential in optimal medication use. | Director/Board Member | 27/02/2015 |
Formation de Barrington John Albert Furr
| The University of Reading | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| MEDIVIR AB | Health Technology |
| GENUS PLC | Process Industries |
| Entreprise privées | 10 |
|---|---|
American Pharmaceutical Co.
American Pharmaceutical Co. Medical DistributorsDistribution Services American Pharmaceutical Co. is a leading advocate for the pharmacy profession and aims to create opportunities for pharmacists to play a key role in integrated patient care. The American company strives to ensure that the pharmacy profession is recognized as essential in optimal medication use. | Distribution Services |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | Health Technology |
Abingworth Management Ltd.
 Abingworth Management Ltd. Investment ManagersFinance Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom. | Finance |
Astex Therapeutics Ltd.
 Astex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Astex Therapeutics Ltd. engages in the provision of drug discovery and development activities. Its proprietary fragment-based drug discovery platform, Pyramid, delivers drug leads on therapeutic targets and disease areas.The company was founded by Harren Jhotin, Roberto Solari, Stephen W. Bunting, Christopher Abell, and Thomas L. Blundell in 1999 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Avesthagen Ltd.
 Avesthagen Ltd. Miscellaneous Commercial ServicesCommercial Services Avesthagen Ltd. provides personalized healthcare through convergence of food, pharma and population genetics. It offers genome analysis, transcriptome analysis, metabolome analysis and lead optimization, and recombinant protein expression services, as well as engages in the generation of stable mammalian cell lines over-expressing a recombinant protein, development of product specific bioassays, and design of novel animal component free production media. The company was founded by Villoo Morwala Zareer Patell on April 20, 1998 and is headquartered in Bangalore, India. | Commercial Services |
Evgen Ltd.
Evgen Ltd. Medical/Nursing ServicesHealth Services Evgen Ltd. develops novel glucosinolate based products for the prevention and treatment of human disease. It engages in the clinical stage drug development that lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. Its activities also include carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The firm holds proprietary technology that enables sulforaphane to be synthesized and then subsequently stabilized for pharmaceutical application. The company was founded by Dr. Stephen Franklin on October 18, 2007 and is headquartered in Liverpool, the United Kingdom. | Health Services |
Almirall Ltd.
 Almirall Ltd. Pharmaceuticals: OtherHealth Technology Almirall Ltd. is an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain. In Almirall they research, develop, produce and market proprietary R&D medicines and those under licence with the aim of improving people's health and wellbeing. They devote big human and economic resources to constant research into new drugs and to obtaining effective and safe products against discomfort and disease. | Health Technology |
| Medicines & Healthcare Products Regulatory Agency | Government |
| Llangarth Ltd. | |
Ipsen Bioinnovation Ltd.
 Ipsen Bioinnovation Ltd. BiotechnologyHealth Technology Ipsen Bioinnovation Ltd. Engages in the research and development of pharmaceutical products. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
